# Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer

Source: https://onco.cc/trials/nct06122584/  
OnCo record `nct06122584` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of PSMA-1007 F-18 run by ABX advanced biochemical compounds GmbH in prostate cancer, now recruiting.

## Summary

Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer is a phase 3 interventional study registered as NCT06122584 by ABX advanced biochemical compounds GmbH, with 380 participants planned, started 2024-06-13. Conditions listed: Prostate Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06122584
- Phase: 3
- Setting: Prospective, Multi-Center Study to Assess the Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed High-Risk or Very-High-Risk Prostate Cancer
- Sponsor: ABX advanced biochemical compounds GmbH
- Enrolled: 380

## Sources

- ClinicalTrials.gov NCT06122584: https://clinicaltrials.gov/study/NCT06122584

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [PSMA-1007 F-18](https://onco.cc/drugs/psma-1007-f18/)
- companies: [ABX advanced biochemical compounds](https://onco.cc/companies/abx-advanced-biochemical-compounds/)

---
JSON: https://onco.cc/api/v1/entities/nct06122584.json